ܠܦܦܐ:PegUricase.png
ܥܓܪܐ ܕܓܠܚܐ: 615 × 599 ܦܩܣܠ. Other resolutions: 246 × 240 ܦܩܣܠ | 493 × 480 ܦܩܣܠ | 788 × 768 ܦܩܣܠ | 1,051 × 1,024 ܦܩܣܠ | 2,192 × 2,136 ܦܩܣܠ.
ܠܦܦܐ ܫܪܫܝܐ (2,192 × 2,136 ܦܩܣܠ، ܥܓܪܐ ܕܠܦܦܐ: 1.65 MB، ܐܕܫܐ ܕ MIME: image/png)
ܦܣܝܩܬ̈ܐ
| Description |
English: A comparison of uricase (pdb:1uox) and PEG-uricase (model). PEG-uricase includes 40 polymers of 10kDa PEG. PEGylation improves its solubility at physiological pH, increases serum half-life and reduces immunogenicity without compromising activity. Upper images show the whole tetramer, lower images show an example of one of the lysines that is PEGylated. (PEG-uricase model from reference[1], only 36 PEG polymers included) |
| ܣܝܩܘܡܐ | |
| ܡܒܘܥܐ | Own work |
| ܣܝܘܡܐ | Evolution and evolvability |
ܦܣܣܐ
I, the copyright holder of this work, hereby publish it under the following license:
This file is licensed under the Creative Commons Attribution 4.0 International license.
- You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
- Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- ↑ (3 January 2008). "PEG-uricase in the management of treatment-resistant gout and hyperuricemia.". Advanced drug delivery reviews 60 (1): 59-68. PMID 17826865.
ܬܫܥܝܬܐ ܕܠܦܦܐ
Click on a date/time to view the file as it appeared at that time.
| ܣܝܩܘܡܐ/ܙܒܢܐ | ܨܘܪܬܐ ܙܥܘܪܬܐ | ܩܝܡ̈ܐ | ܡܦܠܚܢܐ | ܥܘܩܒܐ | |
|---|---|---|---|---|---|
| ܗܫܝܐ | 23:50, 21 ܒܫܒܛ 2015 | | 2,192 × 2,136 (1.65 MB) | Evolution and evolvability | User created page with UploadWizard |
ܡܦܠܚܬܐ ܕܠܦܦܐ
ܠܝܬ ܦܐܬܐ ܕܐܣܪ ܠܗܢܐ ܠܦܦܐ.
ܡܦܠܚܢܘܬܐ ܓܘܢܝܬܐ ܕܠܦܦܐ
The following other wikis use this file:
- Usage on cs.wikipedia.org
- Usage on de.wikipedia.org
- Usage on en.wikipedia.org
- Usage on gl.wikipedia.org
- Usage on ms.wikipedia.org
